Osteologix Signs License To Commercialize Osteoporosis Treatment
This content is restricted. The full version of this content is available for VaBio members only.
Osteologix, Inc. (OTCBB: OLGX), has granted Servier Research Group, the leading French independent pharmaceutical company an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. “I am very happy that we have been able [...]